Nausea is the most common side effect, affecting approximately 15-30% of patients depending on the dose, followed by diarrhea (13-16%), vomiting (6-12%), and constipation (6-7%)
State Medicaid programs will also have access to these medications at these prices. CNBC reported on November 6, 2025, that Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them. A senior administration official explained the rationale to CNBC: We are constraining the access for patients that will benefit clinically from it, weve worked very hard to strike a balance between broad access that just makes sure to capture patients that will benefit clinically. Documentation of these qualifying conditions will be essential for coverage approval
It does not predict exact tolerance or responsemany factors influence individual outcomes
SNAC alone did not affect total T4 exposure, whereas bcCmax was slightly decreased
Response timelines vary from person to person
Gastrointestinal effects are the most common adverse reactions, affecting the majority of patients, particularly during dose initiation and escalation
